Fidaxomicin: New therapy for clostridium difficile associated diarrhea

Formulary

Volumn 46, Issue 8, 2011, Pages 297-308

  Grant, Edward M ^a  

^a Mt Ascutney Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIDAXOMICIN; METRONIDAZOLE; VANCOMYCIN;

ARTICLE; BACTERICIDAL ACTIVITY; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HUMAN; MINIMUM INHIBITORY CONCENTRATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE;

EID: 81155154160     PISSN: 1082801X     EISSN: 19381166     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva J. Clostridium difficile-associated diarrhea and colitis. Infect Control and Hosp Epidemiol. 1995;16:459-477.
2. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005;366:1079-1084.
3. Fordtran JS. Colitis due to Clostridium difficile toxins: underdiagnosed, highly virulent, and nosocomial. Proc (Bayl Univ Med Cent). 2006;19:3-12.
4. Kuijper EJ, Coignard B, Tüll P, for the ESCMID Study Group for Clostridium difficile, EU Member States, and the European Centre for Disease Prevention and Control. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect. 2006;12(Suppl 6):2-18.
5. Johal SS, Hammond J, Solomon K, James PD, Mahida YR. Clostridium difficile associated diarrhea in hospitalised patients: onset in the community and hospital and role of fl exible sigmoidoscopy. Gut. 2004;53:673-677.
6. Fowler S, Webber A, Cooper BS, et al. Successful use of feedback to improve antibiotic prescribing and reduce Clostridium difficile infection: a controlled interrupted time series. J Antimicrob Chemother. 2007;59:990-995.
7. Wilcox MH. Cleaning up Clostridium difficile infection. Lancet. 1996;348:767-768.
8. Centers for Disease Control and Prevention. Frequently asked questions about C. difficile for healthcare providers. Available at: http://www. cdc.gov/HAI/organisms/cdiff/Cdiff_faqs_ HCP.html. Accessed July 7, 2011.
9. Teasley DG, Gerding DN, Olson MM, et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhea and colitis. Lancet. 1983;2:1043-1046.
10. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis. 2006;12:409-415.
11. Musher DM, Aslam S, Logan N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis. 2005;40:1586-1590.
12. Pepin J, Alary ME, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis. 2005;40:1591-1597.
13. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353:2442-2449.
14. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005;353:2433-2441.
15. Pepin J, Saheb N, Coulombe MA, et al. Emergence of fl uoroquinolones as the predominant risk factor for Clostridium diffi - cile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41:1254-1260.
16. Pepin J. Vancomycin for the treatment of Clostridium difficile infection: for whom is this expensive bullet really magic? Clin Infect Dis. 2008;46:1493-1498.
17. Gerding DN. Metronidazole for Clostridium difficile-associated disease: is it okay for Mom? Clin Infect Dis. 2005;40:1598-1600.
18. Wilcox MH, Spencer RC. Clostridium difficile infection: responses, relapses, and re-infections. J Hosp Infect. 1992;22:85-92
19. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31:431-455.
20. Gerding DN, Muto CA, Owens RC Jr. Treatment of Clostridium difficile infection. Clin Infect Dis. 2008;46(Suppl 1):S32-S42.
21. Difi cid [package insert]. San Diego, CA: Optimer Pharmaceuticals, Inc; 2011.
22. Fidaxomicin: Difi micin; Lipiarmycin; OPT 80; OPT-80; PAR 101; PAR-101. Drugs R D. 2010;10:37-45.
23. Theriault RJ, Karwowski JP, Jackson M, et al. Tiacumicins, a novel complex of 18-membered macrolide antibiotics. I. Taxonomy, fermentation and antibacterial activity. J Antibiot (Tokyo). 1987;40:567-574.
24. Babakhani F, Gomez A, Robert N, Sears P. Killing kinetics of fi daxomicin and its major metabolite, OP-1118, against Clostridium diffi - cile. J Med Microbiol. 2011;60:1213-1217. EPub 2011 Feb. 24.
25. Optimer Pharmaceuticals Inc. Anti-infective drugs advisory committee briefi ng document. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisory-Committee/UCM249354.pdf. Accessed July 7, 2011.
26. Shue YK, Sears PS, Shangle S, et al. Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses. Antimicrob Agents Chemother. 2008;52:1391-1395.
27. Louie T, Miller M, Donskey C, Mullane K, Goldstein EJ. Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium diffi - cile infection. Antimicrob Agents Chemother. 2009;53:223-228.
28. Louie TJ, Miller MA, Mullane KM, et al, for the OPT-80-003 Clinical Study Group. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;64:422-431.
29. Babakhani F, Robert N, Shangle S, et al. Antimicrobial activity and postantibiotic effect (PAE) of OPT-80, a new macrocyclic compound, against Clostridium difficile. Presented at: 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; October 30-November 2, 2004; Washington, DC. Poster E-2048.
30. Finegold SM, Molitoris D, Vaisanen ML, Song Y, Liu C, Bolaños M. In vitro activities of OPT-80 and comparator drugs against intestinal bacteria. Antimicrob Agents Chemother. 2004;48:4898-4902.
31. Credito KL, Appelbaum PC. Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species. Antimicrob Agents Chemother. 2004;48:4430-4434.
32. Hecht DW, Galang MA, Sambol SP, Osmolski JR, Johnson S, Gerding DN. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother. 2007;51:2716-2719.
33. Karlowsky JA, Laing NM, Zhanel GG. In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile. Antimicrob Agents Chemother. 2008;52:4163-4165.
34. Citron DM, Babakhani F, Goldstein EJ, et al. Typing and susceptibility of bacterial isolates from the fi daxomicin (OPT-80) phase II study for C. difficile infection. Anaerobe. 2009;15:234-236.
35. Babakhani FK, Seddon J, Robert N, Gomez A, Sears P. Narrow spectrum activity and low fecal binding of OPT-80 and its major hydrolysis metabolite (OP-1118). Presented at: 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; October 30-November 2, 2004; Washington, DC;. Poster E-2076.
36. Biedenbach DJ, Ross JE, Putnam SD, and Jones RN. In vitro activity of fi daxomicin (OPT-80) tested against contemporary clinical isolates of Staphylococcus spp. and Enterococcus spp. Antimicrob Agents Chemother. 2010;54:2273-2275.
37. Babakhani FK, Shangle S, Robert N, Sears P, Shue YK. Resistance development, cross-resistance, and synergy studies of OPT-80. Presented at: 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; October 30-November 2, 2004; Washington, DC. Poster E-2047.
38. AmerisourceBergen Drug Corporation. Available at www. amerisourcebergendrug.com. Accessed July 26, 2011.